Get the Stockscreener App
5.49
12.74%
0.61
Immix Biopharma Inc stock is traded at $5.49, with a volume of 972.26K.
It is up +12.74% in the last 24 hours and up +80.39% over the past month.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$4.88
Open:
$4.93
24h Volume:
972.26K
Relative Volume:
1.77
Market Cap:
$184.51M
Revenue:
-
Net Income/Loss:
$-14.14M
P/E Ratio:
-5.9674
EPS:
-0.92
Net Cash Flow:
$-12.64M
1W Performance:
+29.45%
1M Performance:
+80.39%
6M Performance:
+151.22%
1Y Performance:
+118.33%
1-Day Range:
$4.75
$5.57
1-Week Range:
$3.78
$5.57
52-Week Range:
$1.34
$5.57
Immix Biopharma Inc Stock (IMMX) Company Profile
Name
Immix Biopharma Inc
Sector
Industry
Phone
(888) 958-1084
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
5.495 | 162.52M | 0 | -14.14M | -12.64M | -0.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.17 | 116.04B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
720.87 | 75.97B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.00 | 61.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
903.20 | 56.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.54 | 43.73B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immix Biopharma Inc Stock (IMMX) Latest News
Is Immix Biopharma Inc (IMMX) positioned for future growth? - Setenews
Immix Biopharma, Inc.'s (NASDAQ:IMMX) market cap rose US$18m last week; retail investors who hold 56% profited and so did insiders - simplywall.st
Immix Biopharma (NASDAQ:IMMX) Trading 4.5% Higher – What’s Next? - Defense World
What analysts say about Immix Biopharma Inc stockSector Rotation Strategies & Our Experts Decode Market Noise for You - earlytimes.in
Is Immix Biopharma Inc a good long term investmentMarket Depth Overview & Watch and Learn From Live Trades - earlytimes.in
Will Immix Biopharma Inc. stock benefit from automationJuly 2025 Catalysts & Accurate Intraday Trade Tips - BỘ NỘI VỤ
Immix Biopharma appoints Michael Grabow as chief commercial officer to drive NXC-201 launch - MSN
A significant driver of top-line growth: Immix Biopharma Inc (IMMX) - Setenews
Immix Biopharma Updates Accounting Firm Consents - MSN
Immix Biopharma files updated auditor consents for SEC registration statement - Investing.com Nigeria
Immix Biopharma Inc. (IMMX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Immix Biopharma Updates Auditor Consents for Registration Statement - TradingView
[8-K] Immix Biopharma, Inc. Reports Material Event | IMMX SEC FilingForm 8-K - Stock Titan
Is Variman Global Enterprises Limited Worth Holding Through Market ReversalDividend Cut Warnings & Low Cost Capital Trading - earlytimes.in
We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully - Yahoo Finance
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Will Immix Biopharma Inc. stock rally after Fed decisionsQuarterly Risk Review & Real-Time Buy Zone Alerts - newser.com
Working capital per share of Immix Biopharma, Inc. – NASDAQ:IMMX - TradingView
Can trapped investors hope for a rebound in Immix Biopharma Inc.July 2025 Recap & High Conviction Buy Zone Picks - newser.com
How rising interest rates impact Immix Biopharma Inc. stockPortfolio Value Report & Weekly Hot Stock Watchlists - newser.com
Immix Biopharma’s NXC-201 CAR-T Study: A Potential Game-Changer for AL Amyloidosis - MSN
Will Immix Biopharma Inc. see short term momentum2025 Winners & Losers & Verified Swing Trading Watchlists - newser.com
How Immix Biopharma Inc. stock valuations compare to rivalsJuly 2025 Trends & Safe Capital Growth Tips - newser.com
ETFs Investing in Immix Biopharma, Inc. Stocks - TradingView
What the charts say about Immix Biopharma Inc. todayMarket Rally & AI Enhanced Execution Alerts - newser.com
How Immix Biopharma Inc. stock reacts to bond yieldsPortfolio Performance Summary & Short-Term High Return Ideas - newser.com
Immix Biopharma Inc. stock trendline breakdownEarnings Trend Report & Weekly High Conviction Ideas - newser.com
Immix Biopharma Inc Stock Analysis and ForecastEarnings Beat Highlights & Free Expert Guidance For Growth - earlytimes.in
Why Immix Biopharma Inc. stock appeals to dividend seekers2025 Top Gainers & Daily Profit Maximizing Tips - newser.com
Will Immix Biopharma Inc. stock sustain high P E ratiosEarnings Trend Report & Consistent Income Trade Recommendations - Fundação Cultural do Pará
A History of Outperforming Analyst Forecasts and Beating the Odds: Immix Biopharma Inc (IMMX) - Setenews
Best Biotech Stocks Right Now • Updated Daily - Benzinga
Risk adjusted return profile for Immix Biopharma Inc. analyzedJuly 2025 Price Swings & Capital Efficient Trade Techniques - newser.com
Immix Biopharma appoints Grabow as Chief Commercial Officer - MSN
EBIT per share of Immix Biopharma, Inc. – NASDAQ:IMMX - TradingView
Immix Biopharma Inc Stock (IMMX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immix Biopharma Inc Stock (IMMX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
| Rachman Ilya M | CEO and Chairman |
Jun 18 '25 |
Buy |
2.29 |
2,178 |
4,999 |
1,138,437 |
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
| Hsu Jason | Director |
Dec 23 '24 |
Buy |
2.19 |
40,000 |
87,680 |
893,000 |
| Hsu Jason | Director |
Dec 20 '24 |
Buy |
2.17 |
7,700 |
16,678 |
853,000 |
0.77%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):